Ilyang Pharmaceuticals First Corona Overseas Phase III Clinical Trials in Domestic Medicines
Ilyang Pharmaceuticals First Corona Overseas Phase III Clinical Trials in Domestic Medicines
  • 박상인 기자
  • 승인 2020.05.29 09:41
  • 최종수정 2020.05.29 09:07
  • 댓글 0
이 기사를 공유합니다

Ilyang Pharmaceutical CI

[Infostock Daily= Reporter Park Sang-In] Ilyang Pharmaceutical will begin clinical trials in Russia next month with a new Korean drug called 'Supect' for the treatment of a new coronavirus infection (Corona 19). This is the first time that a clinical trial for Corona 19 treatment is conducted overseas.

Ilyang Pharmaceutical announced on the 28th that it received approval from the Russian government for Phase III clinical trials for Corona 19 treatment. Supect is a treatment for leukemia approved by the Food and Drug Administration in January 2012.

Alfam, the No. 1 pharmaceutical company in Russia, plans to administer Supect to Corona 19 patients at 11 medical institutions in Russia and Belarus.

Corona 19 treatment using domestic new drugs is the first case in which clinical trials are conducted overseas.This is the first time that Corona 19 clinical trials using domestic drugs have been conducted.

It was early this year that Ilyang Pharmaceutical decided to redevelop the drug with Corona 19 treatment. On March 13, the test test confirmed the effect of Corona 19 virus death.

In an experiment conducted by Korea University Medical School, the Corona 19 virus in vitro decreased by 70% within 48 hours of injection of Supect, which is better than Remdesivir.

Clinical trials will begin next month. “The preparation of sample medicines is over in preparation for clinical trials in Russia,” said an Ilyang Pharmaceutical official. “If you send them to Alfam early next month, they will go into clinical trials immediately,” he said.

Reporter Park Sang-In si2020@infostock.co.kr


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.